NCT01612351 2026-03-17
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
UNC Lineberger Comprehensive Cancer Center
Radiation Therapy Oncology Group
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
Stanford University
GlaxoSmithKline
National Cancer Institute (NCI)
GlaxoSmithKline
National Cancer Institute (NCI)
GlaxoSmithKline